Headquartered in Redwood City, CA Fiscal year ends December NASDAQ: CDXS codexis.com
Codexis, Inc. is a biotechnology company that provides enzymatic solutions for efficient and scalable manufacturing of complex therapeutics. The company leverages its proprietary CodeEvolver® technology to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes address real-world challenges in small molecule pharmaceutical manufacturing and nucleic acid synthesis. The company is currently developing its proprietary ECO Synthesis® Manufacturing Platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis's enzymes can drive improvements including higher yields, reduced energy usage and waste generation, improved manufacturing efficiency, and greater sensitivity in genomic and diagnostic applications. The company generates revenue through product sales of its engineered enzymes and through research and development collaborations and licensing arrangements. Codexis is building out an ECO GMP Manufacturing Center to supply siRNA material for preclinical investigations and Phase 1 clinical trials, with full production capability targeted by end of 2027. Updated
In the past week, a couple of gold-mining stocks attracted the attention of insider buyers. Billionaire hedge fund manager John Paulson was a huge insider buyer this past week.
So far in June, some insiders have made colossal purchases of shares of their companies. This big insider buying came largely from beneficial owners.
Toyota has made a huge purchase of shares in an air mobility company. However, it was not the only huge insider buying recently.
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including AstraZeneca, Bumble, McDonald’s and Microsoft.
The top analyst upgrades, downgrades and other research calls from Wednesday include ADP, Broadcom, Vale, VMware, Walgreens and Zebra Technologies.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Abercrombie & Fitch, Altria, Anthem, United Continental, Blackstone and AMAG Pharmaceuticals.
With the markets at or near record highs, the volume of insider selling has reached some of the highest levels this year.
Shares of KiOR slipped to an all-time low of $0.60 a share Tuesday after it filed its annual report with the U.S. Securities and Exchange Commission, a report in which it raised…
Paul Ausick August 9, 2013: U.S. equity markets opened lower this morning and bounced around below the break-even line most of the day. The day’s biggest economic news came from China, where the CPI…
U.S. equity markets opened lower this morning, kicking off a gradual decline that lasted all day. Profit-taking and a lower-than-expected reading on consumer sentiment in the U.S. get the blame. In Europe,…
ThinkstockThe U.S. Environmental Protection Agency (EPA) yesterday proposed new rules and percentage standards for 2013 biofuel consumption. The agency wants U.S. drivers to use 16.55 billion gallons (about 394 million barrels) of…
Any tax legislation worth the name carries with it a host of hangers on that represent special gifts to special interests. The American Taxpayer Relief Act of 2012 is no different. Here…
The three major US stock indexes opened lower this morning following more data from China. Both export and import data fell short, weighing on most Asian markets (more coverage here). There was…
The three major US stock indexes opened mixed this morning following a wealth of data on the Chinese economy. The short version is that the economy is slowing so much and inflation…
Codexis, Inc. is a biotechnology company that provides enzymatic solutions for efficient and scalable manufacturing of complex therapeutics. The company leverages its proprietary CodeEvolver® technology to discover, develop, and enhance novel, high-performance enzymes.
The Wall Street consensus 12-month price target for CDXS is $6.14.
